[1]黄玉斌a,刘　霄a,徐翠香b,等.中晚期恶性肿瘤患者应用PD-1抑制剂多周期治疗对外周血淋巴细胞亚群影响的动态变化研究[J].现代检验医学杂志,2022,37(02):23-27.[doi:10.3969/j.issn.1671-7414.2022.02.005]
　HUANG Yu-bina,LIU Xiaoa,XU Cui-xiangb,et al.Study on the Dynamic Changes of the Effect of PD-1 Inhibitor Multi-cycle Therapy on Peripheral Blood Lymphocyte Subsets in Patients with Advanced Malignant Tumors[J].Journal of Modern Laboratory Medicine,2022,37(02):23-27.[doi:10.3969/j.issn.1671-7414.2022.02.005]
点击复制

中晚期恶性肿瘤患者应用PD-1抑制剂多周期治疗对外周血淋巴细胞亚群影响的动态变化研究()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第37卷
期数:
2022年02期
页码:
23-27
栏目:
论　著
出版日期:
2022-03-15

文章信息/Info

Title:
Study on the Dynamic Changes of the Effect of PD-1 Inhibitor Multi-cycle Therapy on Peripheral Blood Lymphocyte Subsets in Patients with Advanced Malignant Tumors
文章编号:
1671-7414（2022）02-023-05
作者:
黄玉斌1; 2a; 刘　霄2a; 徐翠香2b; 黄晓燕2b; 王建华2a
(1. 西安医学院研究生处，西安 710021；2. 陕西省人民医院，a. 普外二科；b. 陕西省感染与免疫疾病重点实验室，西安 710068）
Author(s):
HUANG Yu-bin1; 2a;  LIU Xiao2a;  XU Cui-xiang2b;  HUANG Xiao-yan2b;  WANG Jian-hua2a
(1. Graduate Division, Xi ’an Medical University, Xi ’an 710021, China; 2a. the Second Department of General Surgery;2b. Shaanxi Key Laboratory of Infection and Immune Diseases, Shaanxi Provincial People’s Hospital,Xi’an 710068, China)
关键词:
恶性肿瘤; 程序性死亡受体-1; 淋巴细胞亚群; 免疫治疗
分类号:
R730.5；R730.43
DOI:
10.3969/j.issn.1671-7414.2022.02.005
文献标志码:
A
摘要:
目的　研究中晚期恶性肿瘤患者应用程序性死亡受体-1（programmed death recepter-1, PD-1）抑制剂治疗过程中淋巴细胞亚群数量的动态变化，探索 PD-1 抑制剂治疗对患者细胞免疫功能及近期疗效的影响。方法　选取2019 年1 月～ 2021 年1 月入住陕西省人民医院肿瘤内科的144 例接受4 个周期治疗的中晚期恶性肿瘤患者，随机分为PD-1单抗+ 化疗（联合治疗）组（n=54）、PD-1 单抗组（n=38）和化疗组（n=52）。流式细胞术检测患者治疗前及每周期治疗后外周血淋巴细胞亚群：T 细胞(CD3+, CD4+, CD8+)，B 细胞（CD19+）及 NK 细胞（CD16+CD56+）数量，应用重复测量方差分析获得不同治疗方案患者淋巴细胞亚群的动态变化趋势。CT 或磁共振成像（MRI）检查评价治疗前及第4 周期治疗后瘤体大小，根据临床效果评价分为治疗有效组（CR 和 PR）和无效组（SD 和 PD），比较三种治疗方案疗效差异。结果　联合治疗组和 PD-1 单抗治疗组患者外周血 CD3+T, CD4+T, CD4+/CD8+ 细胞数量与治疗前相比显著升高，差异均有统计学意义（F联合治疗组=44.978~315.579, FPD-1 单抗治疗组= 15.174~87.558, 均 P<0.05），CD8+T 细胞数量显著降低，差异有统计学意义（F联合治疗组=636.362， FPD-1 单抗治疗组=189.966, 均 P<0.05）。经过4 个周期治疗，联合治疗组和 PD-1 单抗治疗组患者CD4+T ,CD4+/CD8+ 细胞与化疗组相比显著升高，CD8+T 细胞显著降低，差异均有统计学意义（F=3.365~5.362, 均 P<0.05）；联合治疗组 NK 细胞数量与其他两组治疗方案相比显著升高，差异有统计学意义（F=18.062,P<0.05）；三组治疗方案 B 细胞比较，差异无统计学意义（F=0.434, P>0.05）。联合治疗组和 PD-1 单抗治疗组患者治疗有效率高于化疗组（81.48 %, 84.21 % vs 63.46 %），差异有统计学意义（χ2=6.710, P<0.05）。结论 　PD-1 抑制剂联合化疗或单独使用能显著提高中晚期恶性肿瘤患者的淋巴细胞亚群数量，治疗有效率显著高于化疗组，临床获益优于化疗。
Abstract:
Objective 　To study the dynamic changes of lymphocyte subsets in patients with advanced malignant tumors treated with programmed death receptor-1 (programmed death recepter,PD-1) inhibitor, and evaluate the effect of PD-1 inhibitor on cellular immune function and short-term curative effect. Methods　Selected 144 patients with advanced malignant tumors who were admitted to the department of Oncology, Shaanxi Provincial People’s Hospital, and received 4 cycles of treatment from January 2019 to January 2021. They were randomly divided into PD-1 monoclonal antibody+chemotherapy combination therapy group (54 cases), PD-1 monoclonal antibody group (38 cases) and chemotherapy group (52 cases). The dynamic changes of lymphocyte subsets in peripheral blood of patients before and after treatment were detected by flow cytometry, including T (CD3+, CD4+, CD8+), B cells (CD19+) and NK cells (CD16+CD56+). Repeated measurement analysis of variance (ANOVA) was used to analyze the dynamic change trend of lymphocytes in patients. CT or magnetic resonance imaging (MRI) was used to evaluate the tumor size before and after the fourth cycle of treatment. According to the clinical evaluation of different treatment schemes, the tumor size was divided into effective group (CR and PR) and ineffective group (SD and PD), which used to compare the curative effects of the three treatment schemes. Results　The number of CD3+T, CD4+T and CD4+/CD8+ cells in peripheral blood of 54 patients in combined treatment group and 38 patients in PD-1 McAb treatment group were significantly higher than those before treatment（Fcombined treatment group=44.978~315.579; FPD-1 McAb treatment group=15.174 ～ 87.558, all P<0.05）.The number of CD8+T cells were significantly lower than those before treatment（Fcombined treatment group=636.362, FPD-1 McAb treatment group=189.966, all P<0.05）. After 4 cycles of treatment, the number of CD4+T and CD4+/CD8+ cells in combined treatment group and PD-1 McAb group were significantly higher than those in chemotherapy group, while CD8+T cells were significantly lower than those in chemotherapy group（F=3.365 ～ 5.362, all P<0.05）. The number of NK cells in combined treatment group were significantly higher than those in the other two groups, the difference was statistically significant（F=18.062, P<0.05）, but there was no significant difference in B cells among the three groups, the difference was not statistically significant（F=0.434, P>0.05）. The effective rate in the combination treatment group and PD-1 monoclonal antibody treatment group was significantly higher than that in the chemotherapy group （81.48 %, 84.21 % vs 63.46 %）, the difference was statistically significant（χ2=6.710, P<0.05）. Conclusion　PD-1 inhibitors combined with chemotherapy or alone could significantly increase the number of lymphocyte subsets in patients with aadvanced malignant tumors, the effective rate of treatment was significantly higher than that of chemotherapy group, and the clinical benefit is better than that of chemotherapy.

参考文献/References:

[1] TORRE L A, SIEGEL R L, WARD E M, et al. Global cancer incidence and mortality rates and Trends-- An update[J]. Cancer Epidemiology, Biomarkers & Prevention, 2016, 25(1): 16-27.
[2] TARAZI M, GUEST K, COOK A J, et al. Two and five year survival for colorectal cancer after resection with curative intent: A retrospective cohort study [J]. International Journal of Surgery (London, England), 2018, 55: 152-155.
[3] HASSANIPOUR S, DELAM H, ARAB-ZOZANI M, et al. Survival rate of prostate cancer in Asian countries: A systematic review and meta-analysis[J]. Annals of Global Health, 2020, 86(1): 2.
[4] OSIPOV A, SAUNG M T, ZHENG L, et al . Small molecule immunomodulation: the tumor microenvironment and overcoming immune escape[J]. Journal for Immunotherapy of Cancer, 2019, 7(1): 224.
[5] SHAABAN M, OTHMAN H, IBRAHIM T, et al. Immune checkpoint regulators: a new era toward promising cancer therapy[J]. Current Cancer Drug Targets, 2020, 20(6): 429-460.
[6] HAN Yanyan, LIU Dandan, LI Lianhong. PD-1/PDL1 pathway: current researches in cancer[J]. American Journal of Cancer Research, 2020, 10(3): 727-742.
[7] JOSEPH R W, SHILLINGTON A C, LEE T A, et al. Hospitalization and emergency department utilization in patients with advanced melanoma receiving pembrolizumab versus ipilimumab plus nivolumab in US academic centers[J]. Journal of Medical Economics, 2020, 23(2): 132-138.
[8] FUCHS C S, DOI T, JANG R W, et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 Trial [J]. JAMA Oncology, 2018, 4(5): e180013.
[9] XING Y F, PAN X, QIAN B, et al. Expression of PD-1 and PD-L1 in the peripheral blood of advanced nonsmall- cell lung cancer patients and its implications. National Medical Journal of China, 2019, 99(2):111- 114.
[10] DUFFAUD F,THERASSE P.New guidelines to evaluate the response to treatment in solid tumors[J]. Bull Cancer,2000,87:881-886.
[11] DERMANI F K, SAMADI P, RAHMANI G, et al. PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy[J]. Journal of Cellular Physiology, 2019, 234(2): 1313-1325.
[12] RIBAS A, WOLCHOK J D. Cancer immunotherapy using checkpoint blockade[J].Science, 2018, 359 (6382):1350-1355.
[13] HUGO A, MARIA G C, MIREN Z, et al. PD-1 signal transduction pathways in T cells[J]. Oncotarget, 2017, 8(31): 51936-51945.
[14] 郑荣, 何三军, 朱宏才, 等． 食道癌患者血清 CYFRA21-1,CA19-9 和β-hCG 水平联合检测的诊 断价值及与T 淋巴细胞亚群表达的相关性研究[J]. 现代检验医学杂志, 2021, 36（1）：51-53, 91． ZHENG Rong,HE Sanjun,ZHU Hongcai , e t al.Diagnostic value of CYFRA21-1,CA19-9 andβ- hCG in patients with esophageal cancer and its correlation with T lymphocyte subsets [J]. Journal of Modern Laboratory Medicine, 2021, 36(1):51-53,91.
[15] 刘艳霞, 区静怡, 黄颖, 等. 新型冠状病毒肺炎患者 外周血淋巴细胞及其亚群检测的临床意义[J]. 现代 检验医学杂志, 2020, 35(4):94-96, 105. LIU Yanxia, OU Jingyi, HUANG Ying,et al. Clinical significance of detection of peripheral blood lymphocyte and its subgroups in patients with coronavirus disease 2019 [J].Journal of Modern Laboratory Medicine, 2020, 35(4):94-96,105.
[16] DOSSET M, VARGAS T R, LAGRANGE A, et al. PD-1/PD-L1 pathway: an adaptive immune resistance mechanism to immunogenic chemotherapy in colorectal cancer[J]. Oncoimmunology, 2018, 7(6): e1433981.
[17] KUMAGAI S, TOGASHI Y, KAMADA T, et al. The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies[J]. Nature Immunology, 2020, 21(11): 1346-1358.
[18] HEINHUIS K M, ROS W, KOK M, et al. Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors[J]. Annals of Oncology, 2019, 30(2): 219-235.

相似文献/References:

[1]余安运,陶丹,刘夏炎,等.肿瘤标志物在消化系统肿瘤早期诊断中的应用[J].现代检验医学杂志,2015,30(06):133.[doi:10.3969/j.issn.1671-7414.2015.06.041]
　YU An-yun,TAO Dan,LIU Xia-yan,et al.Clinical Value of Blood Serums Tumor Marker in Early Diagnosis of Digestive System Neoplasms[J].Journal of Modern Laboratory Medicine,2015,30(02):133.[doi:10.3969/j.issn.1671-7414.2015.06.041]
[2]马　平,褚　锋.血浆血栓弹力图与纤维蛋白原及D- 二聚体检测对恶性肿瘤患者凝血功能评估的临床价值[J].现代检验医学杂志,2020,35(02):72.[doi:10.3969/j.issn.1671-7414.2020.02.021]
　MA Ping,CHU Feng.Clinical Value of Thrombotic Elastin, Tibrinogen and D-dimer in Evaluatingthe Coagulation Function of Malignant Tumor[J].Journal of Modern Laboratory Medicine,2020,35(02):72.[doi:10.3969/j.issn.1671-7414.2020.02.021]

备注/Memo

备注/Memo:
基金项目： 重点产业创新链（群）- 社会发展领域（编号：2021ZDLSF01-07）；国家自然科学基金青年科学基金项目（编号：81900686）；陕西省人民医院2021 年科技人才支持计划（编号：2021LJ-02）。
作者简介：黄玉斌（1994-），男，硕士研究生在读。主要研究方向为肿瘤免疫，E-mail:huangyb828@163.com。
通讯作者：王建华（1971-），男，博士，主任医师，主要研究方向：肿瘤免疫，E-mail:wangjianhuaman@163.com。
更新日期/Last Update: 1900-01-01